1.58

1.25% -0.02

After Hours: 1.60 0.02 +1.27%

Okyo Pharma Limited (OKYO)

Overview News Price History Discussions Forecast

Okyo Pharma Limited stock is traded at $1.58, with a volume of 53,633. It is down -1.25% in the last 24 hours and down -7.06% over the past month. OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.

Previous Close:

$1.60

Open:

$1.64

24h Volume:

53,633

Relative Volume:

0.22

Market Cap:

$82.92M

Revenue:

Net Income/Loss:

$-4.61M

P/E Ratio:

-12.60

EPS:

-0.1254

Net Cash Flow:

$-3.10M

1W Performance:

-2.47%

1M Performance:

-7.06%

6M Performance:

-28.83%

1Y Performance:

+13.67%

1-Day Range:

$1.5601

$1.67

1-Week Range:

$1.51

$1.73

52-Week Range:

$1.03

$3.349

Okyo Pharma Limited Stock (OKYO) Company Profile

Name

Okyo Pharma Limited

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

Address

Employee

Twitter

Next Earnings Date

2025-12-03

Latest SEC Filings

OKYO's Discussions on Twitter

Compare OKYO vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OKYO Okyo Pharma Limited	1.58	83.97M	0	-4.61M	-3.10M	-0.1254
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-20-26	Initiated	Piper Sandler	Overweight
Dec-08-25	Initiated	B. Riley Securities	Buy

Okyo Pharma Limited Stock (OKYO) Latest News

Mar 25, 2026

How does OKYO Pharma Limited compare to its peersGlobal Markets & Accurate Buy Signal Notifications - baoquankhu1.vn

Mar 25, 2026

Okyo Pharma Limited (OKYO)

Okyo Pharma Limited Stock (OKYO) Company Profile

Compare OKYO vs VRTX, REGN, ALNY, ARGX, INSM

Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades

Okyo Pharma Limited Stock (OKYO) Latest News

How does OKYO Pharma Limited compare to its peersGlobal Markets & Accurate Buy Signal Notifications - baoquankhu1.vn

OKYO Earnings History & Surprises | EPS & Revenue Results | OKYO PHARMA LTD (NASDAQ:OKYO) - ChartMill

OKYO Pharma director acquires additional shares on NASDAQ By Investing.com - Investing.com Australia

OKYO Pharma Chairman Increases Stake Following Positive Neuropathic Corneal Pain Trial - TipRanks

OKYO Pharma executive chairman linked entity acquires additional shares on NASDAQ - Investing.com

OKYO Pharma Announces Chairman and Founder Acquires Shares - The Manila Times

OKYO Pharma director acquires additional shares on NASDAQ - Investing.com UK

OKYO Pharma executive chairman increases stake with share purchase - Proactive Investors

OKYO Pharma (NASDAQ: OKYO) chair adds shares as NCP drug advances - Stock Titan

OKYO Pharma Director Boosts Stake as Lead Eye-Pain Drug Advances Toward Phase 2b/3 - TipRanks

OKYO Pharma Announces Director Acquires Shares - The Manila Times

OKYO Pharma (NASDAQ: OKYO) director boosts stake with 5,000-share purchase - Stock Titan

OKYO Pharma director acquires 30,980 shares, increases total holding By Investing.com - Investing.com India

OKYO Pharma announces director stock purchase - Proactive financial news

OKYO Pharma Executive Increases Stake Following Positive Urcosimod Trial Progress - TipRanks

OKYO Pharma director acquires 30,980 shares, increases total holding - Investing.com

OKYO Pharma Limited Reports Share Acquisition by Chief Development Officer and Advances in Neuropathic Corneal Pain Therapy Development - Quiver Quantitative

OKYO Pharma Announces Chief Development Officer and Director Acquires Shares - The Manila Times

Biotech executive buys more OKYO stock, lifting stake to 108,920 shares - Stock Titan

OKYO Pharma reports quality of life improvements in pain trial By Investing.com - Investing.com India

OKYO Pharma (OKYO) Chief Development Officer reports stock and option holdings - Stock Titan

OKYO Pharma (OKYO) director Cerrone reports 10.5M common-share stake on Form 3 - Stock Titan

OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial - Proactive Investors

Urcosimod Phase 2 NCP data show QoL gains, OKYO Pharma (OKYO) plans Phase 2b/3 - Stock Titan

OKYO Pharma reports quality of life improvements in pain trial - Investing.com

OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain - The Manila Times

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 12.4% in February - MarketBeat

OKYO Pharma (NASDAQ:OKYO) Stock Price Up 1.2%Time to Buy? - MarketBeat

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Consensus Rating of "Hold" from Analysts - MarketBeat

OKYO Pharma prices public offering at $1.85/share to raise up to $20M - MSN

OKYO Pharma Raises About $22 Million After Underwriter Partially Exercises Share Option - The Globe and Mail

OKYO Pharma (OKYO) lifts equity proceeds to $22M after option exercise - Stock Titan

Market Wrap: Is OKYO Pharma Limited a turnaround story2026 Momentum Check & Free Safe Capital Growth Stock Tips - baoquankhu1.vn

Geopolitics Watch: Will Coeptis Therapeutics Holdings Inc. Equity Warrant benefit from rate cutsQuarterly Portfolio Report & AI Based Trade Execution Alerts - baoquankhu1.vn

Published on: 2026-03-07 08:54:47 - baoquankhu1.vn

Setup Watch: Can OKYO Pharma Limited maintain sales growthQuarterly Profit Review & Growth Focused Entry Point Reports - baoquankhu1.vn

Market Rankings: Is OKYO Pharma Limited stock trending bullishIndex Update & Capital Protection Trade Alerts - baoquankhu1.vn

OKYO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress - The Manila Times

OKYO Pharma to present first-in-human urcosimod data at ARVO 2026 - Proactive Investors

OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026 - TipRanks

OKYO Pharma's Urcosimod Selected for Presentation at ARVO 2026 Annual Meeting Following Positive Phase 2a Trial Results for Neuropathic Corneal Pain Treatment - Quiver Quantitative

OKYO (Nasdaq: OKYO) to present Fast Track NCP therapy data at ARVO 2026 - Stock Titan

Analysts Set OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Target Price at $6.00 - Defense World

Piper Sandler Initiates Coverage on OKYO Pharma (NASDAQ:OKYO) - Defense World

OKYO Pharma (NASDAQ:OKYO) Raised to "Strong-Buy" at Piper Sandler - MarketBeat

Piper Sandler initiates OKYO Pharma stock with Overweight rating By Investing.com - Investing.com Nigeria

How OKYO Pharma Limited stock compares to industry benchmarksWeekly Trade Review & Daily Volume Surge Signals - mfd.ru

CEO Moves: Is OKYO Pharma Limited a turnaround story2025 Pullback Review & Weekly High Return Stock Forecasts - baoquankhu1.vn

Okyo Pharma Limited Stock (OKYO) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to OKYO